Cresco Labs (CRLBF) Liabilities and Shareholders Equity (2019 - 2026)

Cresco Labs (CRLBF) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 12.11% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 billion (down 7.99% YoY) and the FY2025 annual result came in at $1.2 billion, down 11.66% from the prior year.
• Liabilities and Shareholders Equity steadied at $1.2 billion in Q1 2026, from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q1 2022 to a low of $1.2 billion in Q4 2025.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity climbed 26.85% — and 2023, when it slipped 20.33%.
• Tracing CRLBF's Liabilities and Shareholders Equity over 5 years: stood at $1.6 billion in 2022, then retreated by 14.22% to $1.4 billion in 2023, then retreated by 0.23% to $1.4 billion in 2024, then decreased by 11.66% to $1.2 billion in 2025, then increased by 0.13% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.